Q4 2022 13F Holders as of 12/31/2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
1.64M
-
Number of holders
-
34
-
Total 13F shares, excl. options
-
19.1M
-
Shares change
-
-122K
-
Total reported value, excl. options
-
$59.9M
-
Value change
-
-$487K
-
Put/Call ratio
-
0.05
-
Number of buys
-
15
-
Number of sells
-
-10
-
Price
-
$3.14
Significant Holders of Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) as of Q4 2022
41 filings reported holding LYRA - Lyra Therapeutics, Inc. - Common Stock, $0.001 par value as of Q4 2022.
Lyra Therapeutics, Inc. - Common Stock, $0.001 par value (LYRA) has 34 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 19.1M shares
.
Largest 10 shareholders include PERCEPTIVE ADVISORS LLC (9.15M shares), Nantahala Capital Management, LLC (2.22M shares), PURA VIDA INVESTMENTS, LLC (2.16M shares), Samsara BioCapital, LLC (1.78M shares), VR Adviser, LLC (924K shares), VANGUARD GROUP INC (791K shares), Soleus Capital Management, L.P. (592K shares), Ikarian Capital, LLC (344K shares), Ensign Peak Advisors, Inc (302K shares), and GEODE CAPITAL MANAGEMENT, LLC (149K shares).
This table shows the top 34 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.